|
 The medical charity Medecins Sans Frontieres (MSF) said its efforts
to get more people to be given the vaccine - developed by the U.S.
drugmaker Merck <MRK.N> and being used in emergency plans in the
Congo epidemic - were being frustrated by "tight controls on supply
and eligibility criteria imposed by the WHO".
"Time is of essence in an outbreak: medical teams should be able to
rapidly provide treatments or vaccines based on what they see on the
ground," MSF's emergency coordinator Natalie Roberts said in a
statement.
"But our capacity... is severely undermined by a rigid system which
is hard to comprehend."
The WHO denied it was rationing the vaccine and said it was working
as hard as any organization to end Congo's deadly Ebola outbreak.
"We partner closely with the DRC government to reach as many
communities and individuals in the outbreak area as possible and are
not limiting access to vaccine," it said.
The Congo Ebola outbreak has killed more than 2,100 people since the
middle of last year, second only to the 2013-16 Ebola outbreak in
West Africa that killed more than 11,300.
[to top of second column] |
The WHO and the Congolese health ministry say that since August
2018, more than 223,000 people have been vaccinated with rVSV-ZEBOV,
the Merck vaccine that has been shown in clinical trials to be
highly protective against Ebola infection.
Congo health authorities also gave the go-ahead on Saturday for
plans to introduce a second Ebola vaccine, made by Johnson & Johnson
<JNJ.N>, to help fight the outbreak.
The Merck shot is being deployed in a strategy known as "ring
vaccination", which aims to control Ebola by identifying and
offering the vaccine to contacts of those likely to be infected.
The WHO said that because Ebola spreads via person-to-person
contact, this is "the most effective means of stopping" its spread,
but MSF's Roberts likened the situation to "giving firefighters a
bucket of water to put out a fire, but only allowing them to use one
cup of water a day".
The WHO said the Merck vaccine eligibility and strategy were
recommended by independent specialists in agreement with Congo.
The plan with addition of the J&J vaccine, it said, is to extend
protection by providing it to "targeted at-risk populations" in
areas where the disease is not yet being actively transmitted.
(Editing by Ed Osmond)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
